Phase 3 trial of lanifibranor for MASH completes enrollment
Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a severe type of fatty…
clinical trial
Phase 1 trial of gene-editing therapy for hepatitis B cleared in US
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
Phase 3 trial of hepatitis D treatment combo enrolls 1st patient
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
Trial testing golexanolone as PBC treatment delayed
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…
Icosabutate fails MASH Phase 2 trial but shows some benefits in liver
Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
Bemnifosbuvir-ruzasvir Phase 3 trials in hepatitis C launch in April
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Efruxifermin reverses MASH-related cirrhosis in Phase 2 trial
Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a still-functioning liver, among adults with metabolic dysfunction-associated…
Rezdiffra reduces scarring in MASH with compensated cirrhosis: Trial
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring for most people with compensated cirrhosis, or irreversible scarring in a still-functioning liver, due to metabolic…
Lanifibranor improves liver health in MASH with diabetes in trial
Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance (empagliflozin) — led to improvements…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
